+39 02 610346.1 - info@newron.com

Latest press releases

  • 10Jan
    Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand

  • 3Jan
    Evenamide met study objectives of good tolerability, safety, and preliminary evidence of efficacy as an add-on therapy for the treatment of schizophrenia- unique MoA

     

  • 23Dec
    Change in Newron’s Senior Management Team

     

  • 21Oct
    US FDA considers Newron’s re-submitted NDA for Xadago® to be a complete, class 2 response to Complete Response Letter PDUFA date March 21, 2017

     

  • 7Oct
    Newron raises CHF26.1 Mio. in a private placement of new shares

     

  • 7Oct
    Newron raises CHF26.1 Mio. in a private placement of new shares

     

View All

Newron share price

Events

  • 4May
    Swiss Biotech Day 2017

    May 4, Congress Center, Basel, CH

  • 24Mar
    16th International Congress on Schizophrenia Research (ICOSR)

    March 24-28, Manchester Grand Hyatt, San Diego, CA, USA

  • 20Mar
    BIO-Europe Spring 2017

    March 20 - 22, 2017 - CCIB Convention Centre - Barcelona, Spain

View Event Calendar